Next Article in Journal
The Role of Systemic Immune-Inflammation Index (SII) in Diagnosing Pediatric Acute Appendicitis
Previous Article in Journal
Evolution and Prognostic Variables of Cystic Fibrosis in Children and Young Adults: A Narrative Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 15
Issue 15
10.3390/diagnostics15151941
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency

by
Anastasios Tsarouchas
1,†,
Constantinos Bakogiannis
1,*,
Dimitrios Mouselimis
1,
Christodoulos E. Papadopoulos
1,
Efstratios K. Theofillogiannakos
1,
Efstathios D. Pagourelias
1,
Ioannis Kelemanis
1,
Aristi. Boulmpou
1,
Antonios P. Antoniadis
1,
Nikolaos Fragakis
2,
Georgios Efthimiadis
3,
Theodoros D. Karamitsos
3 and
Vassilios P. Vassilikos
1,†
1
Third Cardiology Department, Hippokrateion General Hospital, School of Medicine, Aristotle University of Thessaloniki, GR54642 Thessaloniki, Greece
2
Second Cardiology Department, Hippokrateion General Hospital, School of Medicine, Aristotle University of Thessaloniki, GR54642 Thessaloniki, Greece
3
First Cardiology Department, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, GR54642 Thessaloniki, Greece
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Diagnostics 2025, 15(15), 1941; https://doi.org/10.3390/diagnostics15151941 (registering DOI)
Submission received: 22 June 2025 / Revised: 27 July 2025 / Accepted: 30 July 2025 / Published: 2 August 2025
(This article belongs to the Section Clinical Diagnosis and Prognosis)
Browse Figures
Review Reports Versions Notes

Abstract

Background/Objectives: Iron deficiency (ID) is a common and prognostically relevant comorbidity in heart failure with reduced ejection fraction (HFrEF). It contributes to reduced functional status, exercise capacity, and survival. Intravenous ferric carboxymaltose (FCM) improves symptoms, but its effect on cardiac structure and function remains incompletely understood. The aim of this study was to assess the impact of intravenous FCM on echocardiographic indices of left ventricular (LV), left atrial (LA), and right ventricular (RV) morphology and function in HFrEF patients with ID and determine whether these changes correlate with improvements in exercise capacity. Methods: This sub-analysis of the RESAFE-HF registry (NCT04974021) included 86 HFrEF patients with ID (median age 71.8 years, 83% male). Transthoracic echocardiography was performed at baseline and 12 months post-FCM. Parameters assessed included LV ejection fraction (LVEF), LV global longitudinal strain (GLS), LV diastolic function grade, LAVi, LA strain, TAPSE, and RV free wall strain (FWS). Peak VO2 was measured to assess exercise capacity. Results: LVEF improved from 29.3 ± 7.8% to 32.5 ± 10.6% (p < 0.001), LV GLS from −7.89% to −8.62%, and the LV diastolic dysfunction grade improved (p < 0.001). LAVi, peak LA strain, TAPSE, and RV FWS also showed significant improvement. Peak VO2 increased from 11.3 ± 3.2 to 12.1 ± 4.1 mL/min/kg (p < 0.001). Improvements in LVEF, RV FWS, and LV GLS were independent predictors of VO2 increase (p < 0.001, p < 0.001, and p = 0.01, respectively), explaining 42% of the variance. Conclusions: FCM therapy improves biventricular and atrial function, with echocardiographic gains correlating with an enhanced exercise capacity in HFrEF patients with ID.

1. Introduction

Heart failure (HF) is a complex clinical syndrome characterized by the heart’s inability to meet the metabolic demands of the body, typically due to impaired cardiac output or elevated filling pressures. It is estimated that 23 million people globally suffer from heart failure, and heart failure with reduced ejection fraction (HFrEF) amounts to 50% of cases [1]. The gravity of this diagnosis is unquestionable; even in modern cohorts, the 1-year mortality rate of HFrEF patients on optimal treatment is 15–25% [2].
Transthoracic echocardiography (TTE) is an invaluable imaging modality in the workup and prognostication of HF. As the usual first means of quantifying patients’ left ventricular ejection fraction (LVEF) [3,4], TTE enables the quantification of several structural and functional anatomic parameters of the cardiac muscle with significant prognostic value [5]. Left ventricular systolic dysfunction is ubiquitous in patients with HFrEF and can be best quantified with parameters such as the LVEF and, more recently, the left ventricular (LV) global longitudinal strain (GLS). The latter is still comparatively laborious to derive from 2D-TTE views; however, it has proven superior to risk stratification in HFrEF [6]. Additionally, the LV outflow tract velocity time integral can serve as a non-invasive method to assess cardiac output and can provide significant insight in LV systolic function, especially in cases of advanced HF [7].
Diastolic dysfunction is invariably present in HFrEF, and the extent of impairment can be quantified using routinely measured parameters, such as the left atrial volume, the E/A ratio, and the E-wave deceleration time [8,9], as well as the ratio of the transmitral early LV filling velocity to the early diastolic TDI velocity of the mitral annulus (E/e′) [10]. Together, these variables can be used to detect and classify LV diastolic dysfunction in Grades I-III, where Grade I is the least-severe and Grade III corresponds to the most-severe dysfunction [11]. Strain imaging also enables the quantification of the LV diastolic strain rate, another experimental marker of myocardial relaxation, a crucial component of LV diastolic function [12].
Although HFrEF is synonymous with left ventricular dysfunction, it can lead to, and in turn can also be affected by, alterations in the form and function of the left atrium, as well as the right ventricle. The left atrial diameter (LAD), left atrial volume index (LAVi), the left atrial emptying fraction (LAEF) are traditional indices of the left atrial status [13], while the left atrial function index (LAFi) [14] and the peak left atrial strain (LAS) [15] are relatively novel modalities with potential value in the prognostication of HFrEF. Regarding the right ventricle (RV), apart from cases where RV functionality is directly hampered by the injury that caused LF dysfunction, such as an inferior myocardial infarction [16], the increased afterload brought about by pulmonary congestion secondary to LV dysfunction can lead to deterioration of RV functional indices [5]. RV fractional area change (RV FAC) and tricuspid annular plane systolic excursion (TAPSE) are sensitive markers of RV dysfunction and an increased mortality risk [17]. Additionally, RV free wall strain is a relatively new marker with great promise in the risk stratification of HFrEF [18].
Iron deficiency (ID) is increasingly recognized as a source of significant morbidity and mortality in HFrEF [19]. Indeed, several studies have established that ID is an independent predictor of mortality [20,21] and a risk factor for a poor exercise capacity and functional status in patients with HFrEF [22,23]. Furthermore, ID is disconcertingly frequent in HFrEF; more than half of patients with HFrEF fulfill the criteria for ID as defined by the European Society of Cardiology [24]: a serum ferritin value of less than 100 ng/mL, or serum ferritin less than 300 ng/mL with a concurrent transferrin saturation (TSAT) less than 20% [25,26]. According to the latest literature, in patients with HFrEF, absolute iron deficiency is defined as reduced ferritin levels (<100 ng/mL), while functional iron deficiency is defined as a TSAT < 20% [27].
Intravenous iron supplementation with ferric carboxymaltose (FCM) has repeatedly demonstrated promising safety and efficacy in the treatment of ID in HFrEF [28,29,30,31,32,33] and is presented by the 2016 and 2021 ESC guidelines as the preferred treatment option for ID in symptomatic patients with HFrEF [25]. The precise physiological mechanism behind the improvement in patient symptomatology and exercise capacity is not entirely elucidated; our team has previously posited that the restitution of intra-cardiomyocyte iron content can improve their metabolic profile and eventually lead to increased cardiomyocyte electrochemical stability [34,35].
Our team further hypothesized that this would lead to an improvement in myocardial function and a reduction in life-threatening ventricular arrhythmias in patients treated with ferric carboxymaltose. The effect of FCM on arrhythmogenicity was assessed with the Iron Intravenous Therapy in Reducing the burden of Severe Arrhythmias in HFrEF (RESAFE-HF), a prospective, single-center, open-label registry study (NCT04974021).
The present work presents a sub-study of RESAFE-HF that aimed to investigate the effect of IV FCM on conventional and novel ultrasonographic indices of left ventricular (LV), left atrial (LA), and right ventricular (RV) form and function, including parameters derived through two-dimensional, speckle-tracking strain imaging. Another objective was determining if improvements in patients’ echocardiographic indices correlated with patients’ improvement in exercise capacity, as assessed mainly through VO2 max.

2. Materials and Methods

The design of the RESAFE-HF study has been presented before [36]. RESAFE-HF was an investigator-initiated study, designed and conducted independently as a non-commercial clinical study. A departmental research grant from Vifor Pharma Management Ltd. (Glattbrugg, Switzerland). covered the publication costs, lab materials, and medical equipment conducive to the study. Beginning in June 2020, symptomatic patients with HFrEF, ID, and implanted cardiac implantable electronic devices (CIEDs) about to undergo iron supplementation with intravenous ferric carboxymaltose were eligible for inclusion. The participants in the RESAFE-HF study underwent physical examination, blood testing, echocardiography, 6 min walk testing, cardiopulmonary exercise testing (CPET), quality of life quantification with the Kansas City Cardiomyopathy Questionnaire (KCCQ), and EQ-5D-5L assessment at baseline and after 12 months of follow-up and iron supplementation therapy. The RESAFE-HF study design was approved by the appropriate IRBs and performed in accordance with the set of ethical principles outlined in the Declaration of Helsinki [37].

2.1. Inclusion/Exclusion Criteria

All the patients that participated in the RESAFE-HF study were eligible for inclusion in this sub-study. The exclusion criteria for this sub-study were a lack of consent for use of the data beyond the original study or a lack of echocardiographic views as to allow for the quantification of the present study’s echocardiographic endpoints (see below).

2.2. Study Workflow

As part of the original study, patients underwent full transthoracic echocardiography on Vivid S6 and Vivid E9 ultrasound machines (GE Healthcare, Chicago, IL, USA) at baseline and at 12 months.
Parasternal long axis views and apical 4-chamber, 5-chamber, 3-chamber, and 2-chamber views lasting at least 3 full cardiac cycles; in addition to spectral Doppler recordings of mitral flow, pulmonary flow, and left ventricular outflow tract flow; as well as tissue doppler imaging (TDI) of the 4-chamber apical view recordings were saved and archived in the EchoPAC software suite v110.1.3 (GE Healthcare, Chicago, IL, USA).
For the purposes of this sub-study, these echocardiographic studies were used to quantify additional structural and functional indices of the LV, LA, and RV (enumerated in Section 2.3). Informed consent for the use of this data was retrieved from all the participants of the RESAFE-HF study. Similar to the original study protocol, all images were analyzed independently by two attending physicians blinded to patient data and study timepoints (baseline vs. 12 months). All quantitative measurements were performed according to the existing recommendations of the American Society of Echocardiography [38]. The mean of the two observations was accepted. In cases where observations differed by more than 10%, a third expert was called upon. Their measurement was considered final.
CPET was performed with breath-by-breath measurements of respiratory gases using the Ultima CPX system (MGC Diagnostics, Saint Paul, MN, USA). The protocol was bicycle ergometry with steadily increasing power (ramping) tailored for each patient according to the algorithm previously validated by Pretto et al. [39]. The test was considered valid only if the peak achieved respiratory exchange ratio (RER) was equal to or higher than 1. The peak VO2 achieved was recorded.

2.3. Study Endpoints

The endpoints of this sub-study revolved around LV, LA, and RV form and function. LV systolic function was assessed using the LVEF, the LV GLS, and the LVOT VTI, while LV diastolic function was assessed with the E/A ratio (in patients with sinus rhythm), E-wave deceleration time, E/e’ ratio, and diastolic dysfunction grade, as well as the peak early diastolic strain rate. The LV diastolic dysfunction grade was determined based on the flowchart recommended by the 2016 Update from the American Society of Echocardiography and the European Association for patients with reduced LVEF [40]. The grade could not be determined for patients that were in AF during either the baseline or 12-month echocardiographic examination. LV structural information was derived from the LV end-diastolic volume index (LVEDVi) and the LV mass index (LVMi). LV mass was calculated using the Devereux-modified ASE-cube formula: LV mass (g) = 0.8 × {1.04 × [(IVSd + LVIDd + PWTd)3 − (LVIDd)3]} + 0.6, where IVSd, LVIDd, and PWTd represent the septal thickness, LV internal diameter, and posterior wall thickness in diastole, respectively. LA structure and function were assessed using LAD, LAVi, LAEF, LAFI, and LAS, while RV functional indices that served as endpoints included TAPSE, RV FAC, and RV free wall strain.

2.4. Statistical Analysis

Normally distributed continuous variables are reported as mean ± standard deviation and non-normally distributed continuous variables are reported as the median (interquartile range), or the median [interquartile range] when in parentheses. Categorical parameters are reported as the absolute frequency (percentage). If the median of such parameters is 0 (e.g., as with VF episodes per patient per year), they are represented as 5%- or 10%-trimmed mean ± trimmed SD (a choice made with the aim of maximizing readability). Normality was investigated with the Shapiro–Wilk test.
The significance of differences in ordinal and scalar variables was tested with the Wilcoxon signed-rank test, and the McNemar’s test was used for testing differences in paired nominal variables. Missing values due to patient death were imputed with the worst observation of the entire cohort for functional parameters, such as LVEF and strain parameters, while the baseline observation was carried forward for anatomical parameters, such as LAD or LVMi. The significance threshold was set at p < 0.05, and the Hochberg–Benjamini procedure was used to control the false discovery rate (FDR) at 20%. The procedure was applied in clusters grouping together variables quantifying LV systolic, LV diastolic, LA, and RV function. For this reason, some p-values below 0.05 may not be significant, and this is clearly specified in text and tables. RAA was considered a measure of RV functionality when conducting the Hochberg–Benjamini procedure.
To investigate the relative contribution of the improvement of different cardiac function indices to the amelioration of patients’ exercise tolerance, a backwards, stepwise, multivariate linear regression model was created for each category of indices (LV systolic function, LV diastolic function, LA function, and RA function). The dependent variable was the change in VO2 (ΔVO2) during follow-up, while independent variables that were evaluated for inclusion were the differences in echocardiographic indices between baseline and after 12 months e.g., ΔLVEF, ΔLAVi, etc. Only variables with a significant (p < 0.1) correlation with the ΔVO2 were considered candidates for inclusion. The parameters that contributed significantly to each category-specific multivariate model were then inserted into a larger multivariate linear regression model, and stepwise elimination was applied until only significant parameters remained. In the end, the Pratt index was calculated for each significant parameter. The Pratt index allows for the quantification of each parameter’s relative contribution to the ability of the model to explain the variance in the dependent variable: in this case, peak VO2 [41,42].
To explore whether improvements in myocardial deformation were influenced by baseline characteristics or the iron repletion status, we conducted subgroup analyses for each of the three echocardiographic strain parameters: left ventricular global longitudinal strain (LV GLS), left atrial strain (LAS), and right ventricular free wall strain (RV FWS). For each patient, the absolute change from baseline to 12 months (Δ = follow-up–baseline for LAS and RV FWS; baseline–follow-up for LV GLS, given its negative scale) was calculated. Subgroups were defined based on clinically relevant variables: age (equal to and above or below median), sex (male vs. female), ischemic vs. dilated cardiomyopathy, and the presence of functional or absolute iron deficiency at baseline (defined as transferrin saturation [TSAT] < 20% or ferritin <100 µg/L, respectively). For each subgroup comparison, the median strain change and 95% confidence interval were calculated, and between-group differences were assessed using the Mann–Whitney U test. The results were visualized using annotated forest plots.
To evaluate the relationship between iron repletion and myocardial functional improvement, we assessed the correlation between changes in iron indices (ΔTSAT and Δferritin) and changes in strain parameters (ΔLV GLS, ΔLAS, ΔRV FWS) using Spearman’s rank correlation coefficient. Scatter plots with regression lines and 95% confidence intervals were generated to visualize these associations. All the analyses were performed using Python (v3.11) with the pandas, seaborn, matplotlib, and scipy libraries.

3. Results

A total of 86 patients out of the 96 patients that participated in the analysis of RESAFE-HF were included in this sub-study (three patients could not be contacted for consent, and seven were missing critical echocardiographic views, Figure 1). The median age was 71.8 (10.7) years, while 71 (83%) patients were male. Approximately half of the patients (44 patients—51%) had ischemic cardiomyopathy, whereas the other half (42 patients—49%) had a history of dilated cardiomyopathy. At baseline, all the patients were on the maximal tolerable treatment, with 85 (99%) receiving beta-blockers, 68 (79%) aldosterone antagonists, and 43 (50%) sacubitril/valsartan. All the patients had implanted CIEDs, with implantable cardioverter-defibrillators (ICDs) being the most common device (44 patients—51%). The patients participating in the study had several comorbidities, with chronic kidney disease being the most common (84% of the patients), followed by a history of any type of atrial fibrillation (70% of the patients) and dyslipidemia (69% of the patients). Table 1 contains a detailed outline of the patients’ baseline characteristics.
Over the course of a 12-month follow-up period, nine (11%) patient deaths directly attributable to HF were recorded, and a further seven (8%) patients expired due to non-HF-related reasons. The patients received an average of 1.35 ± 0.58 g of iron carboxymaltose over the follow-up period, which led to a significant amelioration of patients’ iron status according to all the available metrics (Table 2); at 12 months, 50 patients (58%) no longer fulfilled the ESC criteria for ID (p < 0.001). Regarding the endpoints of the original study, most improvements in exercise capacity (i.e., 6 min walking distance and peak VO2), quality of life (i.e., total KCCQ score and EQ-5D-5L visual analogue scale), and NT-proBNP hold true in this sub-sample (Supplementary Table S1). All in all, 38 patients had CRT-enabled biventricular pacing, with a satisfactory baseline biventicular pacing rate (median 97% [6.0]), which remained high at 12 months (98.5% [6.8], p = 0.266).

3.1. LV Structural and Functional Parameters

At baseline, the mean LVEF was 29.3 ± 7.8%, and the median LV GLS was −7.89% (3.8). After 12 months of iron supplementation therapy, the mean LVEF increased to 32.5 ± 10.6 (p < 0.001), while the LV GLS improved to −8.62% (4.7) (p = 0.001). Additionally, the median LVEDVi decreased significantly during follow-up, from 89.9 mL/m2 (39.5) to 87.8 mL/m2 (52.3) (p = 0.027).
Regarding LV diastolic function, the diastolic dysfunction grade could be assessed in 59 (69%) patients who were in sinus rhythm or DDD(R) pacing mode for both the baseline and 12-month echocardiograms. These data indicate a significant improvement in patients’ diastolic function—over the course of follow-up, 16 patients (27% of patients in sinus rhythm) with detectable diastolic dysfunction reverted to Grade I (p < 0.017, Figure 2). This improvement is also observable in the constituents of this classification system; patients’ median E/e’ ratio decreased to 13 (8.5) at 12 months compared to 15.1 (7.3) (p < 0.017), while the E-wave deceleration time increased to 188 ms (86) from 173 ms (65) at baseline (p < 0.001). The full range of anatomic and functional indices for the LV can be found in Table 3. The improvements in ferritin and TSAT did not, per se, correlate with improvements in the median LV GLS (Supplementary Figure S4). A subgroup analysis of the change in LV GLS from baseline to 12 months demonstrated consistent improvement across patient categories, including age, sex, etiology of cardiomyopathy, and presence of absolute or functional iron deficiency at baseline with no statistically significant interactions (Supplementary Figure S1).

3.2. LA Structural and Functional Parameters

The median patient LAVi decreased significantly from 37.4 mL/m2 (25.1) to 32 mL/m2 (19.7) after 12 months of follow-up (p < 0.001). An increase in the median patient LAFi was also noted after iron supplementation (20.4 [30.3] at baseline compared to 21.7 [37] at 12 months, p = 0.009). Similarly, the peak LA strain (reservoir strain) improved significantly during follow-up, with the median LA strain reaching 15.1% (11.9) at 12 months compared to 13.9% (12.5) at baseline (p = 0.02). All of the LA indices are presented in Table 4. The improvements in ferritin and TSAT did not, per se, correlate with improvements in the median LA strain (Supplementary Figure S4). A subgroup analysis of the change in LA strain from baseline to 12 months demonstrated consistent improvement across patient categories, including age, sex, etiology of cardiomyopathy, and presence of absolute or functional iron deficiency at baseline with no statistically significant interactions (Supplementary Figure S2).

3.3. RV Structural and Functional Indices

A significant reduction in RV size was observed, with the median RV EDA decreasing to 17 cm2 (6.5) from 18.6 cm2 (8.2) at baseline (p < 0.001). Significant improvement was noted in most of the functional RV indices, with the mean patient TAPSE increasing to 17.6 mm ± 3.5 from 16.4 cm ± 3.6 (p = 0.008) and the median TDI S’ wave velocity reaching 9.2 ± 2.1 cm/sec at 12 months compared to a baseline of 8.2 ± 1.9 (p < 0.001). RV free wall strain also improved significantly; the median value at baseline was 16.9 ± 4.5% and 19.4 ± 5.4% at 12 months (p < 0.001). All the RV indices are presented in detail in Table 5. Right atrial area (RAA) was the only right atrial parameter to be examined in this sub-study, and here too a significant improvement was observed, as the median RAA dropped to 15 cm2 (8) from 16.2 cm2 (7.3) at baseline (p = 0.028). The improvements in ferritin and TSAT did not, per se, correlate with improvements in the median RV free wall strain (Supplementary Figure S4). A subgroup analysis of the change in RV free wall strain from baseline to 12 months demonstrated consistent improvement across the patient categories, including age, sex, etiology of cardiomyopathy, and presence of absolute or functional iron deficiency at baseline with no statistically significant interactions (Supplementary Figure S3).

3.4. Improvement in LV and RV Function as a Mediator of Exercise Capacity Improvement

The patients participating in RESAFE-HF experienced a significant improvement in peak VO2 after 12 months of intravenous iron supplementation, and this holds true in this subgroup as well (excluding nine patients who could not complete the baseline and/or 12-month CPET examination due to musculoskeletal problems or dyspnea at rest, the peak VO2 was 11.3 ± 3.2 mL/min/kg compared to 12.1 ± 4.1 mL/min/kg at 12 months, p < 0.001). As described in the Methods Section, a multivariate model was developed for each category of the echocardiographic indices to examine their contribution to VO2 improvement (abbreviated to ΔVO2) (Supplementary Tables S2–S5). The best-performing indices of each category were candidates for inclusion in a general multivariate linear regression model. The model’s characteristics can be found in Table 6, and the relative contribution of each parameter (its Pratt index) is graphically presented in Figure 3. Overall, improvements in LVEF (p < 0.001), RV FWS (p < 0.001), and LV GLS (p = 0.01) were all independent predictors of an increase in peak VO2, with ΔLVEF and ΔRV GLS being by far the strongest parameters in this regard.

4. Discussion

The aim of this sub-study of RESAFE-HF was to investigate the effect of intravenous iron supplementation with FCM on anatomical and functional indices of the LV, LA, and RV. The main findings are as follows:
  • LV form and systolic function improved significantly after iron supplementation, evidenced by a significant reduction in LVEDVi and improvements in LVEF and LV GLS. Additionally, LV end-diastolic pressures significantly improved, as reflected by the overall LV diastolic dysfunction grade, as well as E/e and E/A, which were evaluated separately.
  • LA size and mechanics improved, as reflected in changes in LAVi, LAFI, and peak LA strain (reservoir strain).
  • RV functional indices improved—a significant reduction in RV EDA and an increase in the median RV free wall strain and RV TDI S’ wave velocity was observed.
  • The improvements in LV and RV systolic function (more specifically LVEF, LV GLS, and RV free wall strain) were independent predictors of an increase in the peak VO2.
To our knowledge, it is the first time such a comprehensive panel of echocardiographic indices covering all aspects of cardiac function have been evaluated simultaneously in patients with HFrEF and ID undergoing iron supplementation with IV FCM. Our results indicate that all aspects of cardiac function exhibited improvement, while FCM’s beneficial effects on the patients’ exercise capacity may be mediated through improvements in RV and LV systolic function.
RCTs, such as FAIR-HF [32], FERRIC-HF [43], CONFIRM-HF [31], and EFFECT-HF [29], offer a multitude of evidence to substantiate the positive influence of IV FCM supplementation on HFrEF patients’ hospitalization rate, exercise capacity, quality of life, and prognostic biomarkers, such as NT-proBNP [28,44]. However, the effect of iron therapy on echocardiographic indices in HFrEF and ID has not been the focus of attention, as none of the aforementioned trials included an echocardiographic endpoint.
What data exist align with our findings, suggesting LV and RV function improvements secondary to intravenous iron supplementation. Martens et al. investigated the effect of IV FCM on the LVEDV and LVEF of patients with HFrEF and ID in the IRON-CRT trial, reporting a significant increase in LVEF to the tune of 4.22% on average [45]. In a later study, Martens et al. investigated the effect of IV FCM on RV functionality in the same group of patients. TAPSE and RV FAC exhibited significant improvements that correlated with the increase in LVEF [46]. Our findings align with both studies, as patients participating in this sub-study of RESAFE-HF experienced a significant improvement in LVEF, TAPSE, and several other LV and RV indices.
A number of cardiac magnetic resonance (CMR) studies investigated the effect of IV FCM on HFrEF and ID patients’ LV functional indices. Nunez et al. [47] were actually able to observe the restitution of myocardial iron stores as a decrease in T2* sequence, which was associated with a non-significant trend towards LVEF improvement—the difference in the median LVEF after approximately 1.5 months was +4.8%, but the small study size (eight patients) limited the impact of these findings. An expanded trial with 53 HFrEF patients with ID undergoing iron therapy with IV FCM corroborated the original observation that the myocardial T2* sequence decreases in response to FCM as a sign of myocardial iron restitution [47]. However, the median +4% increase in LVEF among the patients in the FCM arm compared to the control arm once again failed to reach statistical significance. The RESAFE-HF patients, on average, experienced an improvement in LVEF of similar magnitude. However, our study was adequately powered to achieve statistical significance.
The findings of this study also shed light on the mechanism through which the restitution of iron stores improves exercise capacity in this group of patients. Combined, the improvements in LVEF, LV GLS, and RV free wall strain accounted for 42% of the variation in peak VO2 change between baseline and 12 months. This further establishes that ID is not an ancillary concern but a core pathophysiologic pillar of HFrEF with deleterious effects on LV and RV function. Intravenous iron supplementation with FCM leads to improvement of right and left cardiac function and, ultimately, to a higher peak VO2, reflecting the increased exercise capacity. Our findings are thus compatible with recent evidence indicating that LV GLS correlates with exercise capacity in HFrEF patients [48].
Several of the parameters that improved in our study, including the diastolic dysfunction grade, left atrial volume index (LAVi), left atrial strain, TAPSE, and RV free wall strain, have been previously shown to independently predict mortality and adverse outcomes in patients with HFrEF, underscoring the potential clinical relevance of the observed echocardiographic changes [49].
Naturally, this sub-study has several limitations. The lack of a control arm makes it difficult to appraise the effect of confounding factors that may have influenced the patients’ echocardiographic indices in addition to iron supplementation. However, the patients were already on the maximal tolerated treatment and had not recently had an acute-on-chronic HF episode, as per the exclusion criteria, minimizing the potential effect of statistical epiphenomena, such as regression to the mean, on the study results [50]. As all the patients in this sub-study were required to have an implanted cardiac device (ICD, CRT, or pacemaker) per the original RESAFE-HF protocol, the findings may not be fully generalizable to HFrEF patients without device therapy, although such devices represent a key component of guideline-directed medical therapy in eligible individuals. Additionally, this study relies on transthoracic echocardiography (TTE) to quantify both strain and conventional functional parameters. While TTE remains a widely accepted and accessible tool for cardiac assessment, its accuracy can be influenced by image quality, operator expertise, and inter-vendor variability. Strain imaging in particular is sensitive to tracking quality and vendor-specific post-processing algorithms, while traditional echocardiographic parameters are also subject to interpretive variability and loading conditions [51,52]. Additionally, although several of the observed changes reached statistical significance, their absolute magnitudes were relatively small. These factors should be considered when interpreting the echocardiographic findings and their potential clinical relevance. SGLT2i penetration among the sample was low at baseline and remained low throughout the study as most study visits were concluded prior to their incorporation into the ESC guidelines for chronic heart failure treatment [25]. As a result, potential interactions could not be investigated as part of this study [53]. Tracking patients’ iron content through CMR over the follow-up period would also have been useful as an additional indication that IV FCM supplementation directly acts on LV and RV functionality. Alas, this was not feasible at the time.

5. Conclusions

In conclusion, this sub-study of the RESAFE-HF registry study examined various echocardiographic indices of LV, LA, and RV form and function in patients with HFrEF and ID undergoing intravenous iron therapy with FCM. Both conventional and strain-derived parameters signaled a significant amelioration in patients’ cardiac function. In the form of LVEF, LV GLS, and RV free wall strain gains, this partial restoration of LV and RV function was independently and significantly associated with the concomitant improvement in exercise capacity, as quantified through peak VO2, further highlighting the unique importance of intravenous iron therapy in this group of patients. Further studies will be necessary to establish the causality of this association, preferably including simultaneous non-invasive quantification of myocardial iron content.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/diagnostics15151941/s1. Table S1: RESAFE-HF endpoints in the group of patients participating in this sub-study. Table S2: Characteristics of a multivariate linear regression model developed to investigate associations between ΔVO2 and improvements in echocardiographic indices of LV systolic function. Table S3: Characteristics of a multivariate linear regression model developed to investigate associations between ΔVO2 and improvements in echocardiographic indices of LV diastolic function. Table S4: Characteristics of a multivariate linear regression model developed to investigate associations between ΔVO2 and improvements in LA echocardiographic indices. Table S5: Characteristics of a multivariate linear regression model developed to investigate associations between ΔVO2 and improvements in echocardiographic indices of RV function. Figure S1: Change in Left Ventricular Global Longitudinal Strain (LV GLS) over 12 Months by Subgroup. Figure S2: Change in Right Ventricular Free Wall Strain (RV FWS) over 12 Months by Subgroup. Figure S4: Correlation Between Changes in Iron Parameters and Myocardial Strain Over 12 Months.

Author Contributions

Conceptualization, C.E.P., A.T. and C.B.; methodology, C.E.P., C.B., D.M., E.K.T., E.D.P., I.K., A.B., A.P.A., N.F., G.E., T.D.K. and V.P.V.; validation, E.K.T., E.D.P., I.K., A.B. and A.P.A.; formal analysis, D.M., E.K.T., E.D.P., I.K., A.B. and A.P.A.; investigation, C.E.P., A.T., C.B., D.M., N.F., G.E., T.D.K. and V.P.V.; resources, C.E.P., A.T., C.B., N.F., G.E., T.D.K. and V.P.V.; data curation, C.B. and D.M.; writing—original draft preparation, A.T., C.B. and D.M.; writing—review and editing, C.E.P., E.K.T., E.D.P., I.K., A.B., A.P.A., G.E. and V.P.V.; visualization, A.T. and D.M.; supervision, C.E.P., C.B., E.K.T., E.D.P., I.K., A.B., A.P.A., N.F., G.E., T.D.K. and V.P.V.; project administration, C.E.P., C.B., E.K.T., E.D.P., I.K., A.B., A.P.A., N.F., G.E., T.D.K. and V.P.V.; funding acquisition, C.B. All authors have read and agreed to the published version of the manuscript.

Funding

VPV reports receiving a departmental research grant from Vifor Pharma Management Ltd. (internal grant number 98640), covering publication costs, lab materials, and medical equipment conducive to the study.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Ippokrateion General Hospital of Thessaloniki (approval number 219/12-3-19, approval date 12/03/2019).

Informed Consent Statement

Informed consent was obtained from all the subjects involved in the study.

Data Availability Statement

Data is available upon request.

Acknowledgments

The authors would like to thank the nursing staff of the department for their invaluable contribution to the research effort and, in particular, Third Cardiology Department of Aristotle University of Thessaloniki Smaragda Giannakidou and Efthimia Strati.

Conflicts of Interest

VPV reports receiving a departmental research grant from Vifor Pharma Management Ltd., covering publication costs, lab materials, and medical equipment conducive to the study. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:
AFatrial fibrillation
CPETcardiopulmonary exercise testing
CRTcardiac resynchronization therapy
CMRcardiac magnetic resonance
CIEDcardiac implantable electronic device
E/Aratio of early (E) to late (A) diastolic mitral inflow velocities
E/e′ratio of early mitral inflow velocity to early mitral annular velocity
ESCEuropean Society of Cardiology
FCMferric carboxymaltose
FDRfalse discovery rate
GLSglobal longitudinal strain
HFheart failure
HFrEFheart failure with reduced ejection fraction
IDiron deficiency
ICDimplantable cardioverter-defibrillator
IRBinstitutional review board
LAleft atrium/atrial
LADleft atrial diameter
LAEFleft atrial emptying fraction
LAFIleft atrial function index
LASleft atrial strain
LAVileft atrial volume index
LVleft ventricle/ventricular
LVEDVileft ventricular end-diastolic volume index
LVEFleft ventricular ejection fraction
LVMileft ventricular mass index
LVOT VTIleft ventricular outflow tract velocity time integral
NT-proBNPN-terminal pro-B-type natriuretic peptide
RAright atrium/atrial
RAAright atrial area
RERrespiratory exchange ratio
RVright ventricle/ventricular
RV FACright ventricular fractional area change
RV FWSright ventricular free wall strain
SDstandard deviation
TAPSEtricuspid annular plane systolic excursion
TDItissue doppler imaging
TSATtransferrin saturation
TTEtransthoracic echocardiography
VO2oxygen consumption (often peak VO2 = peak oxygen uptake)

References

  1. Murphy, S.P.; Ibrahim, N.E.; Januzzi, J.L. Heart Failure With Reduced Ejection Fraction. JAMA 2020, 324, 488. [Google Scholar] [CrossRef]
  2. Esteban-Fernández, A.; Anguita-Sánchez, M.; Rosillo, N.; Bernal Sobrino, J.L.; Del Prado, N.; Fernández-Pérez, C.; Rodríguez-Padial, L.; Elola Somoza, F.J. Comprehensive Analysis of Clinical Characteristics, Management, and Prognosis in Patients with Dilated Cardiomyopathy Discharged from Spanish Hospitals. Hell. J. Cardiol. 2024, in press. [Google Scholar] [CrossRef] [PubMed]
  3. Bozkurt, B.; Coats, A.J.S.; Tsutsui, H.; Abdelhamid, C.M.; Adamopoulos, S.; Albert, N.; Anker, S.D.; Atherton, J.; Böhm, M.; Butler, J.; et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition o. Eur. J. Heart Fail. 2021, 23, 352–380. [Google Scholar] [CrossRef] [PubMed]
  4. Rigolli, M.; Anandabaskaran, S.; Christiansen, J.P.; Whalley, G.A. Bias Associated with Left Ventricular Quantification by Multimodality Imaging: A Systematic Review and Meta-Analysis. Open Heart 2016, 3, e000388. [Google Scholar] [CrossRef]
  5. Modin, D.; Andersen, D.M.; Biering-Sørensen, T. Echo and Heart Failure: When Do People Need an Echo, and When Do They Need Natriuretic Peptides? Echo Res. Pract. 2018, 5, R65–R75. [Google Scholar] [CrossRef] [PubMed]
  6. Sengeløv, M.; Jørgensen, P.G.; Jensen, J.S.; Bruun, N.E.; Olsen, F.J.; Fritz-Hansen, T.; Nochioka, K.; Biering-Sørensen, T. Global Longitudinal Strain Is a Superior Predictor of All-Cause Mortality in Heart Failure With Reduced Ejection Fraction. JACC Cardiovasc. Imaging 2015, 8, 1351–1359. [Google Scholar] [CrossRef]
  7. Tan, C.; Rubenson, D.; Srivastava, A.; Mohan, R.; Smith, M.R.; Billick, K.; Bardarian, S.; Thomas Heywood, J. Left Ventricular Outflow Tract Velocity Time Integral Outperforms Ejection Fraction and Doppler-Derived Cardiac Output for Predicting Outcomes in a Select Advanced Heart Failure Cohort. Cardiovasc. Ultrasound 2017, 15, 18. [Google Scholar] [CrossRef]
  8. Pinamonti, B.; di Lenarda, A.; Sinagra, G.; Camerini, F. Restrictive Left Ventricular Filling Pattern in Dilated Cardiomyopathy Assessed by Doppler Echocardiography: Clinical, Echocardiographic and Hemodynamic Correlations and Prognostic Implications. J. Am. Coll. Cardiol. 1993, 22, 808–815. [Google Scholar] [CrossRef]
  9. Xie, G.-Y.; Berk, M.R.; Smith, M.D.; Gurley, J.C.; DeMaria, A.N. Prognostic Value of Doppler Transmitral Flow Patterns in Patients with Congestive Heart Failure. J. Am. Coll. Cardiol. 1994, 24, 132–139. [Google Scholar] [CrossRef]
  10. Hamdan, A.; Shapira, Y.; Bengal, T.; Mansur, M.; Vaturi, M.; Sulkes, J.; Battler, A.; Sagie, A. Tissue Doppler Imaging in Patients with Advanced Heart Failure: Relation to Functional Class and Prognosis. J. Heart Lung Transplant. 2006, 25, 214–218. [Google Scholar] [CrossRef]
  11. Robinson, S.; Ring, L.; Oxborough, D.; Harkness, A.; Bennett, S.; Rana, B.; Sutaria, N.; Lo Giudice, F.; Shun-Shin, M.; Paton, M.; et al. The Assessment of Left Ventricular Diastolic Function: Guidance and Recommendations from the British Society of Echocardiography. Echo Res. Pract. 2024, 11, 16. [Google Scholar] [CrossRef]
  12. Goebel, B.; Haugaa, K.H.; Meyer, K.; Otto, S.; Jung, C.; Lauten, A.; Figulla, H.R.; Edvardsen, T.; Poerner, T.C. Early Diastolic Strain Rate Predicts Response to Heart Failure Therapy in Patients with Dilated Cardiomyopathy. Int. J. Cardiovasc. Imaging 2014, 30, 505–513. [Google Scholar] [CrossRef]
  13. Wierzbowska-Drabik, K.; Kasprzak, J.D.; Haberka, M.; Peteiro, J.; Re, F.; D’Alfonso, M.G.; Mori, F.; Palinkas, E.D.; Agoston, G.; Varga, A.; et al. Left Atrial Volume Changes during Exercise Stress Echocardiography in Heart Failure and Hypertrophic Cardiomyopathy. Hell. J. Cardiol. 2022, 67, 9–18. [Google Scholar] [CrossRef]
  14. Sargento, L.; Vicente Simões, A.; Longo, S.; Lousada, N.; Palma dos Reis, R. Left Atrial Function Index Predicts Long-Term Survival in Stable Outpatients with Systolic Heart Failure. Eur. Heart J. Cardiovasc. Imaging 2017, 18, 119–127. [Google Scholar] [CrossRef]
  15. Jia, F.; Chen, A.; Zhang, D.; Fang, L.; Chen, W. Prognostic Value of Left Atrial Strain in Heart Failure: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med. 2022, 9, 935103. [Google Scholar] [CrossRef]
  16. Thandavarayan, R.A.; Chitturi, K.R.; Guha, A. Pathophysiology of Acute and Chronic Right Heart Failure. Cardiol. Clin. 2020, 38, 149–160. [Google Scholar] [CrossRef] [PubMed]
  17. Monitillo, F.; di Terlizzi, V.; Gioia, M.I.; Barone, R.; Grande, D.; Parisi, G.; Brunetti, N.D.; Iacoviello, M. Right Ventricular Function in Chronic Heart Failure: From the Diagnosis to the Therapeutic Approach. J. Cardiovasc. Dev. Dis. 2020, 7, 12. [Google Scholar] [CrossRef] [PubMed]
  18. Carluccio, E.; Biagioli, P.; Lauciello, R.; Zuchi, C.; Mengoni, A.; Bardelli, G.; Alunni, G.; Gronda, E.G.; Ambrosio, G. Superior Prognostic Value of Right Ventricular Free Wall Compared to Global Longitudinal Strain in Patients With Heart Failure. J. Am. Soc. Echocardiogr. 2019, 32, 836–844.e1. [Google Scholar] [CrossRef] [PubMed]
  19. Jankowska, E.A.; Rozentryt, P.; Witkowska, A.; Nowak, J.; Hartmann, O.; Ponikowska, B.; Borodulin-Nadzieja, L.; Banasiak, W.; Polonski, L.; Filippatos, G.; et al. Iron Deficiency: An Ominous Sign in Patients with Systolic Chronic Heart Failure. Eur. Heart J. 2010, 31, 1872–1880. [Google Scholar] [CrossRef]
  20. Masini, G.; Graham, F.J.; Pellicori, P.; Cleland, J.G.F.; Cuthbert, J.J.; Kazmi, S.; Inciardi, R.M.; Clark, A.L. Criteria for Iron Deficiency in Patients With Heart Failure. J. Am. Coll. Cardiol. 2022, 79, 341–351. [Google Scholar] [CrossRef]
  21. Klip, I.T.; Comin-Colet, J.; Voors, A.A.; Ponikowski, P.; Enjuanes, C.; Banasiak, W.; Lok, D.J.; Rosentryt, P.; Torrens, A.; Polonski, L.; et al. Iron Deficiency in Chronic Heart Failure: An International Pooled Analysis. Am. Heart J. 2013, 165, 575–582.e3. [Google Scholar] [CrossRef]
  22. Ebner, N.; Jankowska, E.A.; Ponikowski, P.; Lainscak, M.; Elsner, S.; Sliziuk, V.; Steinbeck, L.; Kube, J.; Bekfani, T.; Scherbakov, N.; et al. The Impact of Iron Deficiency and Anaemia on Exercise Capacity and Outcomes in Patients with Chronic Heart Failure. Results from the Studies Investigating Co-Morbidities Aggravating Heart Failure. Int. J. Cardiol. 2016, 205, 6–12. [Google Scholar] [CrossRef]
  23. Martens, P.; Nijst, P.; Verbrugge, F.H.; Smeets, K.; Dupont, M.; Mullens, W. Impact of Iron Deficiency on Exercise Capacity and Outcome in Heart Failure with Reduced, Mid-Range and Preserved Ejection Fraction. Acta Cardiol. 2018, 73, 115–123. [Google Scholar] [CrossRef]
  24. Martens, P. The Effect of Iron Deficiency on Cardiac Function and Structure in Heart Failure with Reduced Ejection Fraction. Card. Fail. Rev. 2022, 8, e06. [Google Scholar] [CrossRef]
  25. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Celutkiene, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur. Heart J. 2021, 42, 3599–3726. [Google Scholar] [CrossRef] [PubMed]
  26. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur. Heart J. 2016, 37, 2129–2200. [Google Scholar] [CrossRef]
  27. Anghel, L.; Dinu, C.; Patraș, D.; Ciubară, A.; Chiscop, I. Iron Deficiency Treatment in Heart Failure—Challenges and Therapeutic Solutions. J. Clin. Med. 2025, 14, 2934. [Google Scholar] [CrossRef]
  28. Jankowska, E.A.; Tkaczyszyn, M.; Suchocki, T.; Drozd, M.; von Haehling, S.; Doehner, W.; Banasiak, W.; Filippatos, G.; Anker, S.D.; Ponikowski, P. Effects of Intravenous Iron Therapy in Iron-Deficient Patients with Systolic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Eur. J. Heart Fail. 2016, 18, 786–795. [Google Scholar] [CrossRef] [PubMed]
  29. van Veldhuisen, D.J.; Ponikowski, P.; van der Meer, P.; Metra, M.; Böhm, M.; Doletsky, A.; Voors, A.A.; MacDougall, I.C.; Anker, S.D.; Roubert, B.; et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency. Circulation 2017, 136, 1374–1383. [Google Scholar] [CrossRef] [PubMed]
  30. Anker, S.D.; Kirwan, B.A.; van Veldhuisen, D.J.; Filippatos, G.; Comin-Colet, J.; Ruschitzka, F.; Lüscher, T.F.; Arutyunov, G.P.; Motro, M.; Mori, C.; et al. Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient Data Meta-Analysis. Eur. J. Heart Fail. 2018, 20, 125–133. [Google Scholar] [CrossRef]
  31. Ponikowski, P.; van Veldhuisen, D.J.; Comin-Colet, J.; Ertl, G.; Komajda, M.; Mareev, V.; McDonagh, T.; Parkhomenko, A.; Tavazzi, L.; Levesque, V.; et al. Beneficial Effects of Long-Term Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Symptomatic Heart Failure and Iron Deficiency. Eur. Heart J. 2015, 36, 657–668. [Google Scholar] [CrossRef]
  32. Anker, S.D.; Comin Colet, J.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Lüscher, T.F.; Bart, B.; Banasiak, W.; Niegowska, J.; et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N. Engl. J. Med. 2009, 361, 2436–2448. [Google Scholar] [CrossRef]
  33. Mototani, R.; Watanabe, A.; Kuno, T.; Briasoulis, A. Effect of Intravenous Iron-Carbohydrate Complexes in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: A Meta-Analysis of Randomized Controlled Trials. Hell. J. Cardiol. 2023, 72, 67–69. [Google Scholar] [CrossRef]
  34. Bakogiannis, C.; Briasoulis, A.; Mouselimis, D.; Tsarouchas, A.; Papageorgiou, N.; Papadopoulos, C.; Fragakis, N.; Vassilikos, V. Iron Deficiency as Therapeutic Target in Heart Failure: A Translational Approach. Heart Fail. Rev. 2019, 25, 173–182. [Google Scholar] [CrossRef]
  35. Mouselimis, D.; Bakogiannis, C.; Tsarouchas, A.; Papadopoulos, C.E.; Theofilogiannakos, E.K.; Pagourelias, E.D.; Antoniadis, A.P.; Vassilikou, A.; Balaska, A.; Fragakis, N.; et al. Ferric Carboxymaltose Reduces the Burden of Arrhythmic Events in Heart Failure with Reduced Ejection Fraction: The Role of the Non-Invasive Arrhythmic Biomarkers. Hell. J. Cardiol. 2024. [Google Scholar] [CrossRef]
  36. Bakogiannis, C.; Mouselimis, D.; Tsarouchas, A.; Papadopoulos, C.E.; Theofillogiannakos, E.K.; Lechat, E.; Antoniadis, A.P.; Pagourelias, E.D.; Kelemanis, I.; Tzikas, S.; et al. Iron Therapy and Severe Arrhythmias in HFrEF: Rationale, Study Design, and Baseline Results of the RESAFE-HF Trial. ESC Heart Fail. 2023, 10, 1184–1192. [Google Scholar] [CrossRef]
  37. Rickham, P.P. Human Experimentation: Code of Ethics of W.M.A. BMJ 1964, 2, 177. [Google Scholar] [CrossRef]
  38. Mitchell, C.; Rahko, P.S.; Blauwet, L.A.; Canaday, B.; Finstuen, J.A.; Foster, M.C.; Horton, K.; Ogunyankin, K.O.; Palma, R.A.; Velazquez, E.J. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 2019, 32, 1–64. [Google Scholar] [CrossRef] [PubMed]
  39. Pretto, J.J.; Braun, G.W.; Guy, P.A. Using Baseline Respiratory Function Data to Optimize Cycle Exercise Test Duration. Respirology 2001, 6, 287–291. [Google Scholar] [CrossRef] [PubMed]
  40. Nagueh, S.F.; Smiseth, O.A.; Appleton, C.P.; Byrd, B.F.; Dokainish, H.; Edvardsen, T.; Flachskampf, F.A.; Gillebert, T.C.; Klein, A.L.; Lancellotti, P.; et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2016, 29, 277–314. [Google Scholar] [CrossRef] [PubMed]
  41. Liu, Y.; Zumbo, B.D.; Wu, A.D. Relative Importance of Predictors in Multilevel Modeling. J. Mod. Appl. Stat. Methods 2014, 13, 2–22. [Google Scholar] [CrossRef]
  42. Tuckey, M.R.; Li, Y.; Neall, A.M.; Chen, P.Y.; Dollard, M.F.; McLinton, S.S.; Rogers, A.; Mattiske, J. Workplace Bullying as an Organizational Problem: Spotlight on People Management Practices. J. Occup. Health Psychol. 2022, 27, 544–565. [Google Scholar] [CrossRef]
  43. Okonko, D.O.; Grzeslo, A.; Witkowski, T.; Mandal, A.K.J.; Slater, R.M.; Roughton, M.; Foldes, G.; Thum, T.; Majda, J.; Banasiak, W.; et al. Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. J. Am. Coll. Cardiol. 2008, 51, 103–112. [Google Scholar] [CrossRef]
  44. Beck-da-Silva, L.; Piardi, D.; Soder, S.; Rohde, L.E.; Pereira-Barretto, A.C.; de Albuquerque, D.; Bocchi, E.; Vilas-Boas, F.; Moura, L.Z.; Montera, M.W.; et al. IRON-HF Study: A Randomized Trial to Assess the Effects of Iron in Heart Failure Patients with Anemia. Int. J. Cardiol. 2013, 168, 3439–3442. [Google Scholar] [CrossRef] [PubMed]
  45. Martens, P.; Dupont, M.; Dauw, J.; Nijst, P.; Herbots, L.; Dendale, P.; Vandervoort, P.; Bruckers, L.; Tang, W.H.W.; Mullens, W. The Effect of Intravenous Ferric Carboxymaltose on Cardiac Reverse Remodelling Following Cardiac Resynchronization Therapy—The IRON-CRT Trial. Eur. Heart J. 2021, 42, 4905–4914. [Google Scholar] [CrossRef]
  46. Martens, P.; Dupont, M.; Dauw, J.; Nijst, P.; Bertrand, P.B.; Tang, W.H.W.; Mullens, W. The Effect of Intravenous Ferric Carboxymaltose on Right Ventricular Function–Insights from the IRON-CRT Trial. Eur. J. Heart Fail. 2022, 24, 1106–1113. [Google Scholar] [CrossRef]
  47. Núñez, J.; Miñana, G.; Cardells, I.; Palau, P.; Llàcer, P.; Fácila, L.; Almenar, L.; López-Lereu, M.P.; Monmeneu, J.V.; Amiguet, M.; et al. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial. J. Am. Heart Assoc. 2020, 9, e014254. [Google Scholar] [CrossRef]
  48. D’Ávila, L.B.O.; de Lima, A.C.G.B.; Milani, M.; Milani, J.G.P.O.; Cipriano, G.F.B.; Le Bihan, D.C.S.; de Castro, I.; Cipriano, G., Jr. Left Ventricular Global Longitudinal Strain and Cardiorespiratory Fitness in Patients with Heart Failure: Systematic Review and Meta-Analysis. Hell. J. Cardiol. 2024, 79, 58–69. [Google Scholar] [CrossRef]
  49. Shahnazaryan, S.; Pepoyan, S.; Sisakian, H. Heart Failure with Reduced Ejection Fraction: The Role of Cardiovascular and Lung Ultrasound beyond Ejection Fraction. Diagnostics 2023, 13, 2553. [Google Scholar] [CrossRef]
  50. Barnett, A.G. Regression to the Mean: What It Is and How to Deal with It. Int. J. Epidemiol. 2004, 34, 215–220. [Google Scholar] [CrossRef] [PubMed]
  51. Lyng Lindgren, F.; Tayal, B.; Bundgaard Ringgren, K.; Ascanius Jacobsen, P.; Hay Kragholm, K.; Zaremba, T.; Holmark Andersen, N.; Møgelvang, R.; Biering-Sørensen, T.; Hagendorff, A.; et al. The Variability of 2D and 3D Transthoracic Echocardiography Applied in a General Population. Int. J. Cardiovasc. Imaging 2022, 38, 2177–2190. [Google Scholar] [CrossRef] [PubMed]
  52. Mouselimis, D.; Tsarouchas, A.S.; Pagourelias, E.D.; Bakogiannis, C.; Theofilogiannakos, E.K.; Loutradis, C.; Fragakis, N.; Vassilikos, V.P.; Papadopoulos, C.E. Left Atrial Strain, Intervendor Variability, and Atrial Recurrence after Catheter Ablation: A Systematic and Meta-Analysis. Hellenic J. Cardiol. 2020, 61, 154–164. [Google Scholar] [CrossRef] [PubMed]
  53. Packer, M. Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure. JACC Heart Fail. 2023, 11, 106–114. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 15 01941 g001
Figure 1. Flow diagram for study participants.
Figure 1. Flow diagram for study participants.
Diagnostics 15 01941 g001
Diagnostics 15 01941 g002
Figure 2. Diastolic dysfunction grades of patients at baseline and after 12 months of iron supplementation.
Figure 2. Diastolic dysfunction grades of patients at baseline and after 12 months of iron supplementation.
Diagnostics 15 01941 g002
Diagnostics 15 01941 g003
Figure 3. The relative contribution of left ventricular ejection fraction (LVEF), left ventricular global longitudinal strain (LV GLS), and right ventricular free wall strain to the improvement of peak VO2. The proportion of unaccounted variance was based on R2 values; the relative contribution of explained variance was based on each parameter’s Pratt index.
Figure 3. The relative contribution of left ventricular ejection fraction (LVEF), left ventricular global longitudinal strain (LV GLS), and right ventricular free wall strain to the improvement of peak VO2. The proportion of unaccounted variance was based on R2 values; the relative contribution of explained variance was based on each parameter’s Pratt index.
Diagnostics 15 01941 g003
Table 1. Baseline characteristics of study participants.
Table 1. Baseline characteristics of study participants.
VariableAll Patients
(n = 86)
Age (y)71.8 (10.7)
Sex (male, %)71 (83%)
BMI (kg/m2)29.1 (5.4)
NYHA Class
I0 (0%)
II41 (48%)
III40 (46%)
IV5 (5%)
Ischemic (%)44 (51%)
Pacemaker4 (5%)
ICD44 (51%)
CRT-P6 (7%)
CRT-D32 (37%)
Diabetes37 (43%)
Stroke13 (15%)
CKD72 (84%)
Dyslipidemia59 (69%)
AF60 (70%)
Paroxysmal AF35 (58%)
Permanent AF25 (42%)
ACEi or ARB or ARNi63 (73%)
ACE or ARB only20 (23%)
ARNi43 (50%)
B-blockers85 (99%)
Aldosterone antagonists68 (79%)
SGLT2i6 (7%)
Amiodarone41 (48%)
BMI—body mass index; NYHA—New York Heart Association; ICD—implantable cardioverter defibrillator; CRT-P—cardiac resynchronization therapy (pacing); CRT-D cardiac resynchronization therapy device with cardioverter-defibrillator capability; CKD—chronic kidney disease; AF—atrial fibrillation; ACEi—angiotensin-converting enzyme inhibitors; ARB—angiotensin receptor blockers; ARNi—angiotensin receptor–neprilysin inhibitor; SGLT2i—Sodium/glucose cotransporter-2 inhibitors.
Table 2. Iron-related outcomes at baseline and 12 months.
Table 2. Iron-related outcomes at baseline and 12 months.
VariableBaseline12 Monthsp-Value
Ferritin (μg/L)56.4 (63.7)147.1 (124.6)<0.001
TSAT (%)19 (10.8)24.4 (12.3)<0.001
Functional Iron Deficiency (%)53 (62%)28 (33%)<0.001
Absolute Iron Deficiency (%)74 (86%)26 (30%)<0.001
ESC-defined Iron Deficiency (%)86 (100%)36 (42%)<0.001
Table 3. Outcomes related to LV form and function at baseline and 12 months (n = 86 except where stated).
Table 3. Outcomes related to LV form and function at baseline and 12 months (n = 86 except where stated).
VariableBaseline12 Monthsp-Value
LV anatomical indices
LVEDVi (mL/m2)89.9 (39.5)87.8 (52.3)0.027
LVMi (kg/m2)119.3 (40.3)120.7 (39.7)0.82
LV systolic function indices
LVEF (%)29.3 ± 7.832.5 ± 10.6<0.001
LVOT VTI (m)15.6 (5.1)17.4 (6.6)<0.001
LV GLS (%)−7.89 (3.8)−8.62 (4.7)0.001
LV diastolic function indices
Diastolic dysfunction grade (I/II/III) (n = 59)24 (41%)/21 (36%)/14 (23%)37 (63%)/12 (20%)/10 (17%)0.017
E’ wave velocity (cm/s)0.78 (0.45)0.73 (0.52)0.023
E-wave deceleration time (msec)173 (65)188 (86)0.001
E/A ratio (n = 59)15.1 (7.3)13 (8.5)0.017
LV peak early diastolic strain rate (s−1)0.43 (0.21)0.48 (0.22)0.021
LVEDVi—left ventricular end-diastolic volume index; LVMi—left ventricular mass index; LVEF—left ventricular ejection fraction; LVOT VTI—left ventricular outflow tract velocity time integral; LV GLS—left ventricular global longitudinal strain.
Table 4. Outcomes related to LA form and function at baseline and 12 months.
Table 4. Outcomes related to LA form and function at baseline and 12 months.
VariableBaseline12 Monthsp-Value
LAD (mm)44.4 ± 7.643.6 ± 7.50.117
LAVi (mL/m2)37.4 (25.1)32 (19.7)<0.001
LAEF (%)50 (39.8)44.8 (34)0.096
LAFI20.4 (30.3)21.7 (37)0.009
LA Strain13.9 (12.5)15.1 (11.9)0.02
LAD—left atrial diameter; LAVi—left atrial volume index; LAEF—left atrial emptying fraction; LAFI—left atrial function index; LA—left atrial; strain—peak systolic left atrial strain (reservoir).
Table 5. Outcomes related to right heart form and function at baseline and 12 months.
Table 5. Outcomes related to right heart form and function at baseline and 12 months.
VariableBaseline12 Monthsp-Value
RV EDA (mm2)18.6 (8.2)17 (6.5)<0.001
RAA (mm2)16.2 (7.3)15 (8)0.028
TAPSE (mm)1.64 ± 0.361.76 ± 0.350.008
RV FAC (%)40.1 ± 11.842.5 ± 12.70.111
RV TDI S’ velocity (cm/s)8.2 ± 1.99.2 ± 2.1<0.001
RV free wall strain (%)16.9 ± 4.519.4 ± 5.4<0.001
RV—right ventricular; EDA—end-diastolic area; RAA—right atrial area; TAPSE—tricuspid annular plane systolic excursion; FAC—fractional area change; TDI—tissue doppler imaging.
Table 6. Characteristics of a multivariate linear regression model developed to investigate associations between ΔVO2 and improvements in echocardiographic indices.
Table 6. Characteristics of a multivariate linear regression model developed to investigate associations between ΔVO2 and improvements in echocardiographic indices.
Model ParameterBeta CoefficientStandard Errortp-Value95% Confidence IntervalsPratt Index
LVEF0.150.034.89<0.0010.09–0.210.15
RV free wall strain0.190.053.74<0.0010.09–0.30.14
LV GLS0.370.142.630.010.09–0.650.06
R2 valueVariables excluded through stepwise elimination:
0.42LVOT VTI, E’ wave deceleration time, LAEF, LAFI
LVEF—left ventricular ejection fraction; RV—right ventricular; LV—left ventricular; GLS—global longitudinal strain.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Tsarouchas, A.; Bakogiannis, C.; Mouselimis, D.; Papadopoulos, C.E.; Theofillogiannakos, E.K.; Pagourelias, E.D.; Kelemanis, I.; Boulmpou, A.; Antoniadis, A.P.; Fragakis, N.; et al. Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency. Diagnostics 2025, 15, 1941. https://doi.org/10.3390/diagnostics15151941

AMA Style

Tsarouchas A, Bakogiannis C, Mouselimis D, Papadopoulos CE, Theofillogiannakos EK, Pagourelias ED, Kelemanis I, Boulmpou A, Antoniadis AP, Fragakis N, et al. Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency. Diagnostics. 2025; 15(15):1941. https://doi.org/10.3390/diagnostics15151941

Chicago/Turabian Style

Tsarouchas, Anastasios, Constantinos Bakogiannis, Dimitrios Mouselimis, Christodoulos E. Papadopoulos, Efstratios K. Theofillogiannakos, Efstathios D. Pagourelias, Ioannis Kelemanis, Aristi. Boulmpou, Antonios P. Antoniadis, Nikolaos Fragakis, and et al. 2025. "Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency" Diagnostics 15, no. 15: 1941. https://doi.org/10.3390/diagnostics15151941

APA Style

Tsarouchas, A., Bakogiannis, C., Mouselimis, D., Papadopoulos, C. E., Theofillogiannakos, E. K., Pagourelias, E. D., Kelemanis, I., Boulmpou, A., Antoniadis, A. P., Fragakis, N., Efthimiadis, G., Karamitsos, T. D., & Vassilikos, V. P. (2025). Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency. Diagnostics, 15(15), 1941. https://doi.org/10.3390/diagnostics15151941

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop